Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions

Area of Science:

• Hepatology
• Medical Oncology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) is a primary liver cancer and a leading cause of cancer mortality.
• Late diagnosis is common due to asymptomatic progression, often complicating treatment with underlying cirrhosis.
• Sorafenib's 2007 approval was a milestone, but the therapeutic landscape has since evolved significantly.

Purpose of the Study:

• To review current systemic therapy options for hepatocellular carcinoma (HCC).
• To explore emerging strategies, including novel immunotherapies and targeted agents.
• To emphasize the need for individualized treatment approaches in HCC management.

Main Methods:

• This is a narrative review of current and emerging systemic therapies for HCC.
• The review synthesizes information on first-line, subsequent-line, and novel treatment strategies.
• It considers factors such as tumor biology, liver function, and patient performance status.

Main Results:

• Combination regimens like atezolizumab plus bevacizumab show superior outcomes and are standard first-line options.
• Significant advances include immune checkpoint inhibitors and anti-angiogenic agents.
• Translating molecular insights into personalized HCC treatments remains a challenge.

Conclusions:

• Current HCC systemic therapy includes established and novel immunotherapies and targeted agents.
• Individualized treatment plans are essential for optimizing HCC patient outcomes.
• Future research should focus on personalized medicine and novel therapeutic strategies for HCC.